Tracer library / [90Y]Y-anti-CD66
[90Y]Y-anti-CD66
Also written as [Y-90]Y-Anti-CD66; [Y-90]anti-CD66
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- DTPA-conjugated anti-CD66 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- CD66b-specific monoclonal antibody targeting bone marrow myeloid cells PMID 37509321
- Clinical application
- Radioimmunotherapy for bone marrow targeting as part of conditioning before allogeneic hematopoietic cell transplantation in acute myeloid leukemia, myelodysplastic syndrome, or acute lymphoblastic leukemia PMID 37509321
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.2024 · Bone Marrow Transplant · Clinical study · Phase I
- Optimization of Radiolabeling of a [90Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation.2023 · Cancers (Basel) · Clinical study
- Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.2006 · J Nucl Med · Clinical study
Need this precursor?We can point you to suppliers for [90Y]Y-anti-CD66, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37509321: '[90Y]Y-DTPA-Bn-CHX-A″-anti-CD66-mAb'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.